Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Shares Issued: 2020-2024

Historic Shares Issued for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $20,409.

  • SAB Biotherapeutics' Shares Issued fell 100.00% to -$3 in Q4 2024 from the same period last year, while for Dec 2024 it was $59.7 million, marking a year-over-year decrease of 11.28%. This contributed to the annual value of $20,409 for FY2024, which is 99.97% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Shares Issued of $20,409 as of FY2024, which was down 99.97% from $59.7 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Shares Issued registered a high of $59.7 million during FY2023, and its lowest value of $6,750 during FY2021.
  • For the 3-year period, SAB Biotherapeutics' Shares Issued averaged around $22.5 million, with its median value being $7.7 million (2022).
  • Per our database at Business Quant, SAB Biotherapeutics' Shares Issued soared by 113,689.61% in 2022 and then plummeted by 99.97% in 2024.
  • SAB Biotherapeutics' Shares Issued (Yearly) stood at $9.9 million in 2020, then tumbled by 99.93% to $6,750 in 2021, then spiked by 113,689.61% to $7.7 million in 2022, then spiked by 676.66% to $59.7 million in 2023, then crashed by 99.97% to $20,409 in 2024.